SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
InterMune (nasdaq)ITMN
An SI Board Since March 2000
Posts SubjectMarks Bans Symbol
508 36 0 ITMN
Emcee:  Secret_Agent_Man Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
183The shorts need a hatchet job. The timing of this is perfect. Hit the stock whIRWIN JAMES FRANKEL-3/6/2002
182A nice hatchet job. This is a continuation of rumors spread last year that itrkrw-3/6/2002
181ITMN article - thestreet.com Biotech firm InterMune (ITMN:Nasdaq - news - comIRWIN JAMES FRANKEL-3/6/2002
180sso, I don't see infergen as primarily a hospital drug. Seems to me theyBiomaven-3/5/2002
179Hi, I actually think they have done a pretty good job with sales/marketing Vs psso-3/5/2002
178What about from a clinical perspective? They indicated they plan to run a infergrkrw-3/5/2002
177IJ, Well if they do add another candidate to their portfolio I hope that they pBiomaven-3/4/2002
176Irwin, I see very little chance of a misstep with the current 3 products in desso-3/3/2002
175Hi, Oritavancin does look pretty good. But LLY knew what they were selling - dIRWIN JAMES FRANKEL-3/3/2002
174Irwin, Infergen may be great, but Oritavancin(sp) is GOING to be huge. I hear Lsso-3/3/2002
173"IJ may not think the acquisition of another property is so hot at this timIRWIN JAMES FRANKEL-3/1/2002
172While certainly not the bargain it was about 11 months ago (still can't beliquidditch-2/28/2002
171I bet that management has another drug that they want to buy. Otherwise I can&#IRWIN JAMES FRANKEL-2/28/2002
170Ah, so that so explains the pronounced weakness today, ahead of the announcementBiomaven-2/28/2002
169Thursday February 28, 5:27 pm Eastern Time Press Release SOURCE: InterMune, Inc.IRWIN JAMES FRANKEL-2/28/2002
168>>BRISBANE, Calif., Feb. 5 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdtuck-2/5/2002
167Thursday January 31, 7:32 am Eastern Time Press Release SOURCE: InterMune, Inc. IRWIN JAMES FRANKEL-1/31/2002
166>>BRISBANE, Calif., Jan. 16 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nastuck-1/16/2002
165Thursday January 10, 7:00 am Eastern Time Press Release SOURCE: InterMune, Inc. IRWIN JAMES FRANKEL-1/10/2002
164Tuesday January 8, 7:01 am Eastern Time Press Release SOURCE: InterMune, Inc. InIRWIN JAMES FRANKEL-1/8/2002
163Monday January 7, 6:01 am Eastern Time Press Release SOURCE: InterMune, Inc. IntIRWIN JAMES FRANKEL-1/7/2002
162Short interest jumps: Dec 14 4,555,653 NOv 15 3,088,873IRWIN JAMES FRANKEL-12/27/2001
161Does anyone know when they expect to get the IPF indication? I heard next falsso-12/23/2001
160Friday December 21, 5:21 pm Eastern Time After The Bell - Tech shares steady in IRWIN JAMES FRANKEL-12/21/2001
159<In 2002, we plan to conduct three additional Phase III studies of oritavanciquidditch-12/17/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News